| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Impact BioMedical, Inc.
$0.46
+0.07 (+15.65%)
Market Cap
49.62 M
EPS
0.88
P/E Ratio
0.52 $
Value Trade
11.70 K
-14.78 %
Week
2.95 %
1 Month
-21.33 %
3 Month
1.1 %
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
275.74 K
52 Week Range
0.37 - 0.83
% held by Insiders
0.46 %
% held by Institutions
3.56 %
Enterprise Value
49.61 M
Total Shares
107.82 M
Short %
0.5 %
Float Shares
11.72 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
IBO Clinical Trial Results & History
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in IBO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
IBO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-IBO
Sep 11, 2026▲ +15.6%today
Impact BioMedical Inc (NYSE American: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Ltd. (previously Dr. Ashley’s Ltd.)
Impact BioMedical Inc. announced a 1 for 12.62 reverse stock split effective September 23, 2026, to facilitate its merger with Zoar Ltd. This move aims to enhance the company's listing status and support the merger's completion. Stockholders will receive shares of Zoar Ltd. post-merger, but the reverse split does not assure compliance with NYSE standards.
Read more →-IBO
Apr 3, 2026▲ +8.4%on this news· ran to +20% by day 3
Impact BioMedical Inc. Reports Going Concern Audit Opinion in 2025 10-K Filing While Continuing Strategic Merger Plans
Impact BioMedical Inc. reported a 'going concern' audit opinion in its 2025 10-K filing, indicating financial uncertainties. Despite this, the company is moving forward with plans to merge with Dr. Ashley's Ltd., expected to finalize by July 1, 2026. The announcement does not alter the financial statements for 2025.
Read more →-IBO
Jun 21, 2025▲ +344.6%on this news
Dr Ashleys Limited and Impact BioMedical Inc. Announce Strategic Merger A Strategic Move to Accelerate Market Reach for Innovative Pharmaceutical Patents on
Dr Ashleys Limited and Impact BioMedical Inc. have announced a strategic merger, aiming to enhance their combined market reach and accelerate the development of innovative pharmaceutical treatments. The transaction will involve Dr Ashleys acquiring Impact BioMedical through a reverse merger, resulting in a new entity traded on the NYSE American under the name 'Dr Ashleys Limited.' Both companies have received board approval for the merger, which will allow them to better capitalize on their respective strengths in research and development. The merger is subject to approval from Impact BioMedical's shareholders and regulatory authorities.
Read more →-IBO
Sep 16, 2024Impact BioMedical Inc. Announces Pricing of Initial Public Offering
Impact BioMedical Inc. has announced the pricing for its initial public offering (IPO), offering 1,500,000 shares at $3.00 per share. The shares are scheduled to start trading on the NYSE American under the ticker symbol 'IBO' on September 16, 2024. Additionally, the company has provided the underwriters a 45-day option to purchase 225,000 additional shares at the same price. The IPO is expected to close on September 17, 2024, pending customary closing conditions.
Read more →Competitive Position
How IBO ranks across every disease it competes inCompetitive Position is a premium feature
See how IBO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial